Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

Arthritis and Rheumatism

Volumn 58, Issue 11, 2008, Pages 3402-3412

  Inman, Robert D ^a   Davis Jr , John C ^b   Van Der Heijde, Désirée ^c   Diekman, Laura ^d   Sieper, Joachim ^e   Sung, Il Kim ^f   Mack, Michael ^g   Han, John ^g   Visvanathan, Sudha ^g   Xu, Zhenhua ^g   Hsu, Benjamin ^g   Beutler, Anna ^g   Braun, Jürgen ^h  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TEXAS   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Pusan National University Hospital   (South Korea)

^g CENTOCOR INC   (United States)

^h RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GOLIMUMAB; HYDROXYCHLOROQUINE; INDOMETACIN; ISONIAZID; LIVER ENZYME; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL WITHDRAWAL; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BASAL CELL CARCINOMA; BLEPHARITIS; CHRONIC OTITIS MEDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HEART INFARCTION; HEPATITIS; HUMAN; HYPERTENSION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIVER TOXICITY; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; MULTICENTER STUDY; NAUSEA; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SHORT FORM 36; SIDE EFFECT; SORE THROAT; SUICIDE ATTEMPT; THORAX PAIN; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 55849108826     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.23969     Document Type: Article

References (20)

1. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
2. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al, for the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
3. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
4. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
5. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:964-75.
6. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino JJ, et al. Golimumab, a new, human, TNF-α antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study [abstract]. Arthritis Rheum 2007;56:4308-9.
7. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
8. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
9. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
10. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
11. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
12. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
13. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
14. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988;41:313-21.
15. Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 2008;47:897-900.
16. Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor α antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007;66:1393-7.
17. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. Magnetic resonance imaging (MRI) in predicting a major clinical response to anti-TNF-treatment in ankylosing spondylitis. Ann Rheum Dis 2007. E-pub ahead of print.
18. Van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489-93.
19. Calin A, Edmunds L, Kennedy LG. Fatigue in ankylosing spondylitis: why is it ignored? J Rheumatol 1993;20:991-5.
20. Van Tubergen A, Coenen J, Landewe R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 2002;47:8-16.